Postdoctoral Research Fellow in tumor cell biology (ref 309856)

University of Oslo; Norway; Presencial; NOK 550 000 - 650 000; Tempo integral

Resumo da oferta

University of Oslo invites applications for a 100% 3-year Postdoctoral Research Fellow position in tumor cell biology within the Collas Lab at the Department of Molecular Medicine, Division of Biochemistry, Institute of Basic Medical Sciences. The project focuses on microproteins and their role in cancer biology, with in vivo work and collaboration with Oslo University Hospital.

The successful applicant will contribute to mechanistic studies, cell-based assays, and model systems to advance

Responsabilidades

• Examine how microproteins regulate RUNX2 using cancer cell lines and PDX mouse tumor models.
• Collaborate with the research team and external partners at Oslo University Hospital to optimize cell-based assays and in vivo setups.

Descrição da oferta de emprego

Organisation/Company University of Oslo Research Field Medical sciences Researcher Profile Recognised Researcher (R2) Positions Postdoc Positions Application Deadline 4 Nov 2026 - 23:00 (Europe/Oslo) Country Norway Type of Contract Temporary Job Status Full-time Hours Per Week 37,5 Is the job funded through the EU Research Framework Programme? Not funded by a EU programme Is the Job related to staff position within a Research Infrastructure? No

Offer Description

A 100% 3-year Postdoctoral Research Fellow position in tumor cell biology is available in the research group of Prof. Philippe Collas, project group of Dr. Marie Rogne, at the Department of Molecular Medicine, Division of Biochemistry, Institute of Basic Medical Sciences, University of Oslo ( Collas Lab ). The position is funded through the Norwegian Cancer Society.

Within the Institute, the Division of Biochemistry consists of a young and active community of nine research groups working on cancer biology, chromatin and nuclear dynamics, nuclear architecture, membrane trafficking, and adipocyte, muscle and vascular biology, using human, fly and mouse models.

The overall goal of the project is to establish knowledge of the innovative therapeutic potential of microproteins in advanced prostate cancer. In this context, the successful applicant will, in collaboration with the research team and external partners at Oslo University Hospital, examine how specific microproteins regulate the activity of the transcription factor RUNX2, using cancer cell lines and PDX mouse tumor models, for various cell-based assays. The work involves in vivo setups and is expected to necessitate optimizations.